Shinichiro Motohashi

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 10

Top Topics

Signaling Pathway

Top Venues

Cancer research communications

Cancer immunology, immunotherapy : CII

Cancer immunology research

This page only lists publications with an associated author ORCID identifier.

Publications

Mariko Takami, Takahiro Aoki, Katsuhiro Nishimura, Hidekazu Tanaka, Atsushi Onodera, Shinichiro Motohashi
Anti-Vα24Jα18 TCR antibody tunes iNKT cell responses to target and kill CD1d-negative tumors in an FcγRII (CD32)-dependent manner. Cancer research communications (2024)
Mariko Takami, Takahiro Aoki, Katsuhiro Nishimura, Hidekazu Tanaka, Atsushi Onodera, Shinichiro Motohashi
Anti-Vα24Jα18 TCR Antibody Tunes iNKT Cell Responses to Target and Kill CD1d-negative Tumors in an FcγRII (CD32)-dependent Manner. Cancer research communications 4 (2) (2024)
Mariko Takami, Takahiro Aoki, Katsuhiro Nishimura, Hidekazu Tanaka, Atsushi Onodera, Shinichiro Motohashi
Anti-Vα24Jα18 TCR Antibody Tunes iNKT Cell Responses to Target and Kill CD1d-negative Tumors in an FcγRII (CD32)-dependent Manner. Cancer research communications 4 (2) (2024)
Mariko Takami, Takahiro Aoki, Katsuhiro Nishimura, Hidekazu Tanaka, Atsushi Onodera, Shinichiro Motohashi
Anti-Vα24Jα18 TCR Antibody Tunes iNKT Cell Responses to Target and Kill CD1d-negative Tumors in an FcγRII (CD32)-dependent Manner. Cancer research communications 4 (2) (2024)
Ryo Koyama-Nasu, Toshinori Nakayama, Masahiro Kiuchi, Ami Aoki, Yangsong Wang, Yukiyoshi Mita, Ichita Hasegawa, Yukihiro Endo, Atsushi Onodera, Kiyoshi Hirahara, Shinichiro Motohashi, Toshinori Nakayama
CD69 imposes tumor-specific CD8+ T-cell fate in tumor-draining lymph nodes. Cancer immunology research (2023)
Takahide Toyoda, Toshiko Kamata, Kazuhisa Tanaka, Fumie Ihara, Mariko Takami, Hidemi Suzuki, Takahiro Nakajima, Takayuki Ikeuchi, Yohei Kawasaki, Hideki Hanaoka, Toshinori Nakayama, Ichiro Yoshino, Shinichiro Motohashi
Phase II study of α-galactosylceramide-pulsed antigen-presenting cells in patients with advanced or recurrent non-small cell lung cancer. Journal for immunotherapy of cancer 8 (1) (2021)
Ayaka Hara, Ryo Koyama-Nasu, Mariko Takami, Takahide Toyoda, Takahiro Aoki, Fumie Ihara, Masayoshi Kobayashi, Seiichiro Hirono, Tomoo Matsutani, Toshinori Nakayama, Yasuo Iwadate, Shinichiro Motohashi
CD1d expression in glioblastoma is a promising target for NKT cell-based cancer immunotherapy. Cancer immunology, immunotherapy : CII 70 (5) (2020)
Takahiro Aoki, Mariko Takami, Tomozumi Takatani, Kiwamu Motoyoshi, Ayana Ishii, Ayaka Hara, Takahide Toyoda, Reona Okada, Moeko Hino, Ryo Koyama-Nasu, Masahiro Kiuchi, Kiyoshi Hirahara, Motoko Y Kimura, Toshinori Nakayama, Naoki Shimojo, Shinichiro Motohashi
Activated invariant natural killer T cells directly recognize leukemia cells in a CD1d-independent manner. Cancer science 111 (7) (2020)
Kazuaki Harada, Fumie Ihara, Mariko Takami, Toshiko Kamata, Naoko Mise, Hiroko Yoshizawa, Tomoro Hishiki, Takeshi Saito, Keita Terui, Mitsuyuki Nakata, Shugo Komatsu, Takayuki Ikeuchi, Toshinori Nakayama, Hideo Yoshida, Shinichiro Motohashi
Soluble factors derived from neuroblastoma cell lines suppress dendritic cell differentiation and activation. Cancer science 110 (3) (2019)
Toshiko Kamata, Shigetoshi Yoshida, Mariko Takami, Fumie Ihara, Hiroko Yoshizawa, Takahide Toyoda, Yuichiro Takeshita, Seiichi Nobuyama, Yukiko Kanetsuna, Tetsuo Sato, Ichiro Yoshino, Shinichiro Motohashi
Immunological features of a lung cancer patient achieving an objective response with anti-programmed death-1 blockade therapy. Cancer science 111 (1) (2019)